To investigate whether cabergoline ( Cb@ ) , a dopamine agonist , reduces ovarian hyperstimulation syndrome ( OHSS ) in high-risk women undergoing assisted reproductive technology ( ART ) , and to analyze whether cabergoline affects the outcome of ART .